DxS appoints Jeff Devlin as new Chief Operating Officer

29-Jan-2009 - United Kingdom

DxS Ltd has announced the appointment of Jeff Devlin as Chief Operating Officer.

Prior to DxS, Jeff held positions as Executive VP and Executive Committee member of Shire Pharmaceuticals, where he played a key role in strategy and integration. Before this he was a Partner in Ernst and Young’s life science division. Jeff has a BSc in Physics from the University of Edinburgh and an MSc in Marketing from the University of Strathclyde.

The appointment is one of a number planned for 2009, continuing DxS’ expansion which has seen the company’s workforce more than double in size in the last twelve months with new manufacturing space taken at their Manchester site and a global distribution deal agreed with Roche Molecular Diagnostics.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures